Education
About Us
Working with TipRanks
Follow Us
Fulgent Genetics Inc (FLGT)
NASDAQ:FLGT
Earnings Data
Report Date
May 02, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.01Same Quarter Last Year
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: 9.88%
|Next Earnings Date:May 02, 2025
Earnings Call Sentiment|Positive
Fulgent Genetics showed strong revenue growth in the fourth quarter and made significant progress in clinical trials and strategic partnerships. However, the company reported a GAAP loss and expects lower operating margins due to continued investment in growth. Despite these challenges, the company is optimistic about future opportunities and growth potential.Company Guidance
During the Fulgent Genetics Q4 2024 earnings call, the company provided guidance and key metrics for their business outlook. They are anticipating a 10% year-over-year growth in core revenue for 2025, estimating total core revenue to be approximately $310 million, with $187 million from Precision Diagnostics, $106 million from anatomic pathology, and $17 million from biopharma services. The company expects non-GAAP gross margins to slightly exceed 40% and anticipates a GAAP EPS loss of approximately $1.95 per share. Additionally, they project a cash burn of around $25 million for their therapeutics development business. Fulgent's management expressed optimism about their clinical pipeline, including the phase two trial of FID-007 and the initiation of a phase one trial for FID-022, with total clinical trial costs estimated at $18 million combined. They also highlighted strategic partnerships that could drive future growth but are not yet fully factored into their guidance.Record Fourth Quarter Growth
Fulgent Genetics delivered a fourth-quarter revenue growth of 14% year over year and 6% sequentially, exceeding annual core revenue guidance of $280 million.
Successful Clinical Trials
In 2024, Fulgent Genetics began a phase two clinical trial of FID-007 with encouraging preliminary results. They also submitted an IND for FID-022, cleared by the FDA, with the first patient enrollment expected in Q2 2025.
Strong Biopharma Services Growth
Biopharma services grew 56% quarter over quarter, from $3.9 million in Q3 to $6.1 million in Q4.
Significant Partnerships
Fulgent Genetics announced a partnership with Foundation Medicine to launch two tests using Fulgent's proprietary technology.
Improved Operational Efficiency
Fulgent Genetics relocated their lab to Coppell, Texas, and consolidated their New York lab, improving operational efficiency.
---
FLGT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FLGT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $15.69 | $15.45 | -1.53% |
| Nov 08, 2024 | $22.02 | $19.43 | -11.76% |
| Aug 02, 2024 | $23.57 | $25.06 | +6.32% |
| May 03, 2024 | $21.24 | $21.50 | +1.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fulgent Genetics Inc (FLGT) report earnings?
Fulgent Genetics Inc (FLGT) is schdueled to report earning on May 02, 2025, TBA Not Confirmed.
What is Fulgent Genetics Inc (FLGT) earnings time?
Fulgent Genetics Inc (FLGT) earnings time is at May 02, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FLGT EPS forecast?
FLGT EPS forecast for the fiscal quarter 2025 (Q1) is -0.18.
---